COPD
-
Presenters to share insights into new ventilation reimbursement criteria
Peter Gay, MD, FCCP, will chair a session about the implications of revised coverage guidelines for noninvasive positive pressure ventilation devices for patients with COPD.
-
Clinicians to examine opportunities to confront dyspnea in COPD
Muhammad A. Zafar, MD, MSc, will chair a session exploring how dyspnea—more than just shortness of breath and discomfort—can be part of a downward spiral accompanying COPD.
-
Prevention of COPD exacerbations with an eosinophilic endotype
With the recent US approval of the IL-5-directed monoclonal antibody mepolizumab as an add-on therapy for patients with COPD, the era of COPD biologics is undeniably here.
-
Persistent mucus plugs linked to faster lung function decline in COPD
Investigator Sofia Mettler, MD, MPH, said the findings may point to a potential intervenable pathology in obstructive airway disease.
-
Sessions to explore next generation of care in COPD
Presentations across dozens of sessions will provide clinicians with an unparalleled opportunity to refine their expertise and help patients manage this disease, said CHEST Airways Disorders Curriculum Group Chair Shahid Sheikh, MD, FCCP.
-
COURSE trial shows importance of biomarker testing in COPD
While overall the trial was negative, Meilan King Han, MD, MS, and Sanjay Ramakrishnan, MBBS, PhD, said it demonstrated the promise of tezepelumab for patients with baseline blood eosinophil counts ≥ 150 cells/µL.
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
-
CMS decision positively impacts the future of home ventilation coverage
CMS recently released a decision on coverage for noninvasive ventilation devices for patients with COPD, a process that CHEST has been closely involved in.
-
For the neuromuscular disease community, ventilation coverage victory doesn’t carry over
Patient advocate Spero Koulouras said he believes CMS home ventilation coverage criteria for patients with disorders such as ALS are still ambiguous enough that private insurers have interpreted them to deny and delay coverage.
-
MATINEE shows positive results for mepolizumab in COPD
Experts Frank Sciurba, MD, FCCP, and Gerard J. Criner, MD, FCCP, said clinicians have a second option for treating patients with high type 2 inflammation now that the FDA has approved the drug for those with an eosinophilic phenotype.
